10:34 AM EDT, 09/27/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that Dupixent, or dupilumab, has received approval from the US Food and Drug Administration for treating chronic obstructive pulmonary disease.

The FDA's approval of Dupixent as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype was based on two phase 3 trials that showed a 30% and 34% cut in the annualized rate of moderate or severe COPD exacerbations over 52 weeks, the drugmakers said.

Shares of Regeneron were up 2.2%, while Sanofi ( SNY ) rose 1.4% in recent trading.

Price: 1062.31, Change: +22.35, Percent Change: +2.15